Form S-8 Mersana Therapeutics,

Go back to Form S-8 Mersana Therapeutics,

Mersana (MRSN) PT Lowered to $11 at Wedbush

March 12, 2019 7:19 AM EDT

Wedbush analyst David Nierengarten lowered the price target on Mersana (NASDAQ: MRSN) to $11.00 (from $15.00) while maintaining a Outperform rating.

Ph 1b dose escalation data from MRSNs XMT-1536 is expected in 2Q19MRSN set to unveil their next clinical candidate in H2:19... More